India Pharma Outlook Team | Monday, 25 August 2025
Piramal Pharma Solutions (PPS), a prominent international Contract Development and Manufacturing Organization (CDMO) and member of Piramal Pharma Ltd., and NewAmsterdam Pharma Company N.V., have opened a dedicated oral solid dosage (OSD) suite at the PPS Sellersville, Pennsylvania facility.
The Sellersville site is one of PPS’s main drug product facilities and offers integrated development and manufacturing services with a large number of dosage forms, including OSDs. The new suite is a multi-million-dollar investment to improve operational efficiencies and enable NewAmsterdam Pharma to deliver its investigational fixed dose combination (FDC) therapy, a non-statin treatment for LDL-C, assuming regulatory approval.
The facility upgrade comprises a new suite with new technology, as well as new space configuration for turnkey, multilayer tablet production. The suite is equipped for granulation, compression, tableting, and coating — providing all the capabilities needed for high-precision, high-volume FDC product production.
The collaboration does not just stop at Sellersville. Piramal Pharma's Ahmedabad PPDS site is being involved in product development work and Piramal Pharma's Pithampur site has provided dual sourcing capability.
Also Read: Takeda Pharma Plans to Launch Clinical Trials in India Soon
Peter DeYoung, CEO of Piramal Global Pharma said, "Expanding our manufacturing has a profound impact on our production capacity and commitment to patient centricity." Douglas Kling, COO of NewAmsterdam Pharma, added, "By investing in Sellersville, we are ensuring the precision manufacturing needed to satisfy future commercial demand, and furthering our collaboration with Piramal Pharma Solutions."
The new suite will do more than strengthen supply chains and compressed production cycle times; it is estimated to create more than 20 new jobs in Sellersville within the next five years, having a positive economic impact locally.
Together, Piramal Pharma Solutions and NewAmsterdam Pharma, are looking to scale innovation and efficiency to accelerate patient access to innovative new therapies around the world.
